By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix said after the close of the market on Monday that it has entered into a securities purchase agreement to sell almost $6.8 million of newly issued shares.

The firm will sell a combination of common stock and warrants in a private placement to accredited investors.

Net proceeds from the transaction will be used to fund growth initiatives and for general working capital purposes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.